🧪 New Hope in a Pill: Actinogen’s Oral Alzheimer’s Treatment Enters Pivotal Trial Phase

A promising new oral therapy for Alzheimer’s disease is now recruiting participants across the United States, offering fresh hope to families affected by this devastating condition. Actinogen Medical’s XanaMIA Phase 2b/3 trial is testing the efficacy of Xanamem®, a once-daily pill designed to slow cognitive decline by targeting cortisol—the brain’s stress hormone.

🧠 What Is Xanamem?

Xanamem® (emestedastat) is a first-in-class oral drug that inhibits the enzyme 11β-HSD1, which regulates cortisol production in the brain. Elevated cortisol is linked to memory loss and cognitive decline in Alzheimer’s disease. By reducing cortisol in key brain regions like the hippocampus, Xanamem aims to preserve cognitive function without disrupting the body’s normal hormone balance.

🔬 About the XanaMIA Trial

• Design: Randomized, double-blind, placebo-controlled
• Treatment Period: 36 weeks, followed by a 24-month open-label extension
• Participants: 220 individuals with mild to moderate Alzheimer’s
• Primary Endpoint: Clinical Dementia Rating – Sum of Boxes (CDR-SB)
• Trial Sites: 20 locations across the U.S.

The trial is designed to be low-burden—no lumbar punctures or frequent brain scans. Participants take a daily pill and attend regular clinic visits for cognitive assessments.

👥 Who Can Join?

Eligible participants must:

• Be 50 years or older
• Have a diagnosis of mild to moderate Alzheimer’s
• Have a study partner who can attend clinic visits
• Not have received anti-amyloid antibody therapy in the past 6 months

Among the 30 Trial Locations

• California: Carlsbad, Orange, Sherman Oaks
• Colorado: Denver, Englewood
• Florida: Delray Beach, Miami, New Port Richey, Orlando, The Villages
• Georgia: Decatur
• New Jersey: Toms River
• New York: Albany, Staten Island
• Ohio: Dayton, Independence
• Oregon: Portland
• Rhode Island: East Providence
• Texas: Austin
• Washington: Bellevue

📈 What’s Next?

Actinogen has enrolled over 100 participants and plans an interim analysis in January 2026, with final results expected by late 2026. If successful, Xanamem could become a game-changing oral therapy—either as a standalone treatment or in combination with existing drugs like Leqembi.

🧭 Why It Matters

Unlike anti-amyloid therapies that require infusions and carry risks of brain swelling, Xanamem offers a simple, oral alternative with a strong safety profile. It’s been studied in over 400 people across eight trials and has shown potential benefits for both Alzheimer’s and depression.

For families seeking a less invasive, more accessible treatment, this trial could mark a turning point.

🔗 How to Learn More

You can find out more about the XanaMIA trial in the following ways:

• ✅ Check eligibility online
• 📧 Email Actinogen’s clinical trials team: clinicaltrials@actinogen.com.au
• 🌐 Visit the XanaMIA trial website